On July 9, 2018, the U.S. Food and Drug Administration (FDA) is hosting a public meeting on Patient-Focused Drug Development for Chronic Pain at its White Oak campus in Maryland. FDA is interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA is particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies. Please register early to attend the meeting in person or view the live webcast.
For more information, please visit: Patient-Focused Drug Development.